Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)

• Company Description    MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland. Number of Employees: 91

• Price / Volume Information    Yesterday's Closing Price: $1.04 Daily Weekly Monthly 20 Day Moving Average: 1,026,902 shares Shares Outstanding: 107.12 (millions) Market Capitalization: $111.41 (millions) Beta: 1.37 52 Week High: $2.40 52 Week Low: $0.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.71% 14.81% 12 Week 31.21% 21.30% Year To Date -32.90% -37.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9713 Key West Avenue Suite 400 - ROCKVILLE,MD 20850 USA ph: 301-944-1700 fax: 301-944-1703 ir@maxcyte.com http://www.maxcyte.com

• General Corporate Information    Officers Maher Masoud - Chief Executive Officer and President Richard Douglas - Chairman Douglas Swirsky - Chief Financial Officer Yasir Al-Wakeel - Director Will Brooke - Director Peer Information MaxCyte, Inc. (CORR.) MaxCyte, Inc. (RSPI) MaxCyte, Inc. (CGXP) MaxCyte, Inc. (BGEN) MaxCyte, Inc. (GTBP) MaxCyte, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 57777K106 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 107.12 Most Recent Split Date: (:1) Beta: 1.37 Market Capitalization: $111.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.66 Price/Cash Flow: - Price / Sales: 3.45 EPS Growth vs. Year Ago Period: 60.00% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -7.11% vs. Previous Quarter: 32.21% ROE 03/31/26 - -20.03 12/31/25 - -22.15 09/30/25 - -23.50 ROA 03/31/26 - -17.14 12/31/25 - -18.98 09/30/25 - -20.22 Current Ratio 03/31/26 - 12.04 12/31/25 - 8.30 09/30/25 - 7.74 Quick Ratio 03/31/26 - 11.29 12/31/25 - 7.77 09/30/25 - 7.27 Operating Margin 03/31/26 - -110.15 12/31/25 - -124.38 09/30/25 - -132.57 Net Margin 03/31/26 - -121.16 12/31/25 - -135.14 09/30/25 - -132.57 Pre-Tax Margin 03/31/26 - -121.16 12/31/25 - -135.14 09/30/25 - -132.57 Book Value 03/31/26 - 1.57 12/31/25 - 1.61 09/30/25 - 1.69 Inventory Turnover 03/31/26 - 0.82 12/31/25 - 0.79 09/30/25 - 0.84 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©